“It’s important for patients to be educated on (next-generation sequencing), because the more we know about a patient’s cancer, the better we can design a personalized treatment plan,” says an expert.

Market conditions remain tough for biotech companies, but Twist continues to perform well compared to peers. Twist Bioscience's second quarter results were strong, driven by NGS demand, and the ...

2022 saw a surge of interest and competition in the next-gen sequencing (NGS) industry, as established companies were joined by a hungry group of new platforms. Today, researchers who sequence DNA ...

In the United States, healthcare professionals classify a disease as rare if it affects fewer than 200,000 individuals. As of August 7, 2024, the U.S. population consists of just under 336.9 million ...

[more than 13% of patients with advanced NSCLC and an aSV] "would have experienced a meaningful delay of several weeks or more if RNA-NGS and DNA-NGS had been performed sequentially rather than ...

Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and Meta-Analysis Given the benefits and likely future applications, there is an ...